Predicting chemotherapeutic response to small-cell lung cancer of platinum compounds by thallium-201 single-photon emission computerized tomography
1998

Using Thallium-201 SPECT to Predict Chemotherapy Response in Lung Cancer

Sample size: 21 publication Evidence: moderate

Author Information

Author(s): Y Tokuchi, H Isobe, H Takekawa, T Hanada, T Ishida, S Ogura, K Itoh, M Furudate, K Saito, Y Kawakami

Primary Institution: Hokkaido University

Hypothesis

The degree of TI uptake to tumour in 201Tl scintigraphy is associated with the response to chemotherapy with platinum compounds.

Conclusion

Thallium-201 SPECT could be a useful indicator of response to chemotherapy with platinum compounds in lung cancers.

Supporting Evidence

  • The overall response rate was 62%, with a complete response rate of 33%.
  • The retention index was significantly higher in patients with good responses compared to those with no change or progressive disease.
  • Intracellular thallium uptake was reduced in cells treated with ouabain, indicating the role of Na,K-ATPase in drug sensitivity.

Takeaway

Doctors used a special scan to see how much thallium a lung cancer tumor took in, which helped them understand how well the cancer would respond to treatment.

Methodology

Patients underwent 201TI-SPECT scans before receiving chemotherapy, and the retention index was calculated to evaluate the relationship between TI uptake and chemotherapy response.

Limitations

The study did not account for the effects of etoposide, which was used in combination with platinum compounds.

Participant Demographics

Patients with small-cell lung carcinomas, aged 56 to 82, with both limited-stage and extensive-stage disease.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication